EVEREST MED(01952) patent rights of Nifukang make positive progress

15:25 27/02/2026

The original research product Nafukang of Cloudtop Xin Yao has made key progress in patent protection, and the Guangzhou Intellectual Property Court has ordered the relevant generic drug companies to immediately stop the infringement behavior and remove the listings.

On February 27, EVEREST MED (01952) announced a key breakthrough in the patent protection of its original research product Budenatide enteric capsules (Nifukang). The Guangzhou Intellectual Property Court issued a civil ruling on February 26, 2026, fully supporting the company's pre-litigation preservation application and ordering the related generic drug companies to immediately stop infringing behaviors and cease online sales. The ruling is effective immediately. EVEREST MED welcomes the court's fair ruling and will continue to uphold intellectual property rights in accordance with the law, promoting innovative therapies to benefit more patients.

HK Stock Market Move | INNOCARE (09969) rose by more than 4% in the final trading session, completion of patient enrollment in Phase III clinical trial of BCL2 inhibitor combined with Apatinib.

Citibank: The budget confirms that the scope of Hong Kong's economic recovery will expand, with fiscal reserves expected to remain stable.

Caitong: Maintains "Buy" rating on TRIP.COM-S (09961) Performance exceeds expectations and internationalization drive continues.

HK Stock Market Move | INNOCARE (09969) rose by more than 4% in the final trading session, completion of patient enrollment in Phase III clinical trial of BCL2 inhibitor combined with Apatinib.

Citibank: The budget confirms that the scope of Hong Kong's economic recovery will expand, with fiscal reserves expected to remain stable.

Caitong: Maintains "Buy" rating on TRIP.COM-S (09961) Performance exceeds expectations and internationalization drive continues.